ARTICLE | Translation in Brief
Tagging out
A protein degradation method by Bradner, Gray could improve target validation
March 26, 2018 4:01 PM UTC
C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over a protein’s expression than traditional genetic or pharmacological approaches.
Bradner is president of the Novartis Institutes for BioMedical Research (NIBR). Gray is a professor of cancer biology at Dana-Farber Cancer Institute and a professor of biological chemistry and molecular pharmacology at Harvard Medical School. ...
BCIQ Target Profiles